Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing

By LabMedica International staff writers
Posted on 17 Sep 2026

Standardized biomarker reporting and molecular profiling are central to pathology-driven cancer care, but evolving practices require laboratories to keep reporting templates current. More...

These templates capture information needed for diagnosis, staging, and treatment while aligning with expert guidance. To support this work, the College of American Pathologists has detailed Cancer Protocol updates addressing breast cancer biomarker reporting and gastrointestinal stromal tumor molecular testing.

The College of American Pathologists (CAP) has introduced revisions to 14 Cancer Protocols to align cancer reporting with evolving World Health Organization (WHO) classifications and advances in precision medicine. The Q3 release focuses on breast cancer biomarkers and gastrointestinal stromal tumors (GISTs). According to CAP, the updates reflect advances in precision oncology and laboratory accreditation.

CAP’s Cancer Protocols are updated quarterly to incorporate guidance from leading standard-setting organizations, including the WHO and the American Joint Committee on Cancer (AJCC). These evidence-based tools are designed to help pathologists produce accurate, standardized reports that support diagnosis, staging, treatment decisions, and patient care. A full Summary of Revisions is available on cap.org.

Among the most significant changes, the Breast Phyllodes Tumor protocol is now required for accreditation when reporting malignant phyllodes tumors. The revised protocol incorporates WHO 6th Edition updates, modifies specific reporting elements, and updates staging and margin reporting. CAP notes that these changes are intended to bring reporting into closer alignment with current classifications.

The release also updates the Breast Biomarker Protocol, including revisions to estrogen receptor (ER), progesterone receptor (PgR), and HER2 scoring and reporting criteria. These changes are designed to support consistent reporting of biomarkers that help guide breast cancer treatment decisions. In addition, CAP expanded molecular testing and reporting capabilities within its GIST protocols, adding new reporting options for NTRK fusion gene analysis, enhancing KIT and PDGFRA testing and reporting, and supporting reporting for GISTs across all anatomic sites.

Related Links
College of American Pathologists


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.